CO2018012497A2 - Anticuerpos de interferón beta y usos de los mismos - Google Patents

Anticuerpos de interferón beta y usos de los mismos

Info

Publication number
CO2018012497A2
CO2018012497A2 CONC2018/0012497A CO2018012497A CO2018012497A2 CO 2018012497 A2 CO2018012497 A2 CO 2018012497A2 CO 2018012497 A CO2018012497 A CO 2018012497A CO 2018012497 A2 CO2018012497 A2 CO 2018012497A2
Authority
CO
Colombia
Prior art keywords
interferon beta
beta antibodies
antibodies
antigen
fragments
Prior art date
Application number
CONC2018/0012497A
Other languages
English (en)
Inventor
Stefano V Gulla
Christine Huard
Janet Elizabeth Buhlmann
Juan Carlos Almagro
Sreekumar R Kodangattil
Steven A Greenberg
Edward Roland Lavallie
Eric M Bennett
Lidia Mosyak
James Perry Hall
Anthony John Coyle
Original Assignee
Pfizer
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Brigham & Womens Hospital Inc filed Critical Pfizer
Publication of CO2018012497A2 publication Critical patent/CO2018012497A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se relaciona con anticuerpos, o fragmentos de los mismos de enlace al antígeno, que de manera específica enlazan el interferón beta (IFNβ). Dichos anticuerpos, o fragmentos de los mismos de enlace al antígeno, son útiles para varios propósitos terapéuticos o de diagnóstico.
CONC2018/0012497A 2016-04-29 2018-11-21 Anticuerpos de interferón beta y usos de los mismos CO2018012497A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662329327P 2016-04-29 2016-04-29
US201662339709P 2016-05-20 2016-05-20
US201762483669P 2017-04-10 2017-04-10
PCT/US2017/030089 WO2017189983A1 (en) 2016-04-29 2017-04-28 Interferon beta antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CO2018012497A2 true CO2018012497A2 (es) 2018-12-14

Family

ID=59215947

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0012497A CO2018012497A2 (es) 2016-04-29 2018-11-21 Anticuerpos de interferón beta y usos de los mismos

Country Status (29)

Country Link
US (2) US10829553B2 (es)
EP (2) EP3448419B1 (es)
JP (2) JP6799076B2 (es)
KR (1) KR102527840B1 (es)
CN (1) CN109069606B (es)
AU (1) AU2017258492B2 (es)
BR (1) BR112018072118A2 (es)
CA (1) CA2965652A1 (es)
CO (1) CO2018012497A2 (es)
DK (1) DK3448419T3 (es)
ES (1) ES2950288T3 (es)
FI (1) FI3448419T3 (es)
HR (1) HRP20230605T1 (es)
HU (1) HUE063621T2 (es)
IL (1) IL262244B2 (es)
MX (1) MX2018013222A (es)
MY (1) MY194084A (es)
NZ (1) NZ747225A (es)
PE (1) PE20190371A1 (es)
PH (1) PH12018502275A1 (es)
PL (1) PL3448419T3 (es)
PT (1) PT3448419T (es)
RU (1) RU2750454C2 (es)
SA (1) SA518400327B1 (es)
SG (1) SG11201809456UA (es)
SI (1) SI3448419T1 (es)
TW (1) TWI776808B (es)
WO (1) WO2017189983A1 (es)
ZA (1) ZA201806682B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190371A1 (es) 2016-04-29 2019-03-08 Pfizer Anticuerpos de interferon beta y usos de los mismos
MX2020002070A (es) 2017-08-22 2020-03-24 Sanabio Llc Receptores solubles de interferon y usos de los mismos.
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
US20220144957A1 (en) * 2019-01-31 2022-05-12 Immunecent Biotechnology, Inc. Novel anti-ifnar1 antibodies
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
CN114733455B (zh) * 2022-04-15 2023-02-14 北京田园奥瑞生物科技有限公司 一种利用生物改性β-环糊精纳米磁颗粒进行快速哺乳动物***分型的方法
WO2024062420A1 (en) * 2022-09-22 2024-03-28 Pfizer Inc. METHODS OF TREATMENT WITH IFNß ANTIBODIES

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6682896B1 (en) * 1988-10-14 2004-01-27 Schering Aktiengesellschaft Peptides representing epitopic sites on r-IFN-β, antibodies thereto and uses thereof
ATE132502T1 (de) * 1988-10-14 1996-01-15 Berlex Lab Peptide, die epitope auf r-ifn-beta repräsentieren, antikörper dagegen, und ihre anwendung
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL108584A (en) 1994-02-07 2008-03-20 Yeda Res & Dev Cloning of the interferon-binding protein ALPHA / BETA
ZA9811070B (en) * 1997-12-08 2000-07-03 Genentech Inc Type I interferons.
ATE395413T1 (de) 2001-12-03 2008-05-15 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
NZ540730A (en) 2002-12-24 2010-09-30 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
MX342240B (es) 2011-04-07 2016-09-21 Genentech Inc Anticuerpos anti-fgfr4 y metodos de uso.
CN102898521A (zh) * 2011-07-26 2013-01-30 上海市免疫学研究所 抗β-干扰素单克隆抗体及其应用
US10647756B2 (en) 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies
KR20180020296A (ko) * 2015-06-26 2018-02-27 바이오버라티브 유에스에이 인코포레이티드 자가면역 및 동종면역 장애를 치료하는 방법
PE20190371A1 (es) 2016-04-29 2019-03-08 Pfizer Anticuerpos de interferon beta y usos de los mismos

Also Published As

Publication number Publication date
WO2017189983A1 (en) 2017-11-02
KR20190003625A (ko) 2019-01-09
JP7102489B2 (ja) 2022-07-19
ES2950288T3 (es) 2023-10-06
FI3448419T3 (fi) 2023-08-02
DK3448419T3 (da) 2023-06-26
HUE063621T2 (hu) 2024-01-28
PH12018502275A1 (en) 2019-09-09
RU2750454C2 (ru) 2021-06-28
TW201739764A (zh) 2017-11-16
PE20190371A1 (es) 2019-03-08
MX2018013222A (es) 2019-04-22
ZA201806682B (en) 2022-05-25
KR102527840B1 (ko) 2023-05-03
US20210163588A1 (en) 2021-06-03
CN109069606A (zh) 2018-12-21
EP3448419B1 (en) 2023-06-07
JP2019516366A (ja) 2019-06-20
PL3448419T3 (pl) 2023-09-04
IL262244A (en) 2018-11-29
AU2017258492A1 (en) 2018-10-25
SI3448419T1 (sl) 2023-10-30
SG11201809456UA (en) 2018-11-29
JP6799076B2 (ja) 2020-12-09
AU2017258492B2 (en) 2023-12-07
EP4273165A3 (en) 2023-12-20
HRP20230605T1 (hr) 2023-09-29
MY194084A (en) 2022-11-11
CA2965652A1 (en) 2017-10-29
US11858986B2 (en) 2024-01-02
NZ747225A (en) 2022-07-29
IL262244B2 (en) 2024-01-01
RU2018141839A (ru) 2020-05-29
EP4273165A2 (en) 2023-11-08
US10829553B2 (en) 2020-11-10
SA518400327B1 (ar) 2022-12-03
US20170313769A1 (en) 2017-11-02
EP3448419A1 (en) 2019-03-06
JP2021040642A (ja) 2021-03-18
TWI776808B (zh) 2022-09-11
BR112018072118A2 (pt) 2019-03-19
IL262244B1 (en) 2023-09-01
PT3448419T (pt) 2023-07-26
CN109069606B (zh) 2022-07-01
RU2018141839A3 (es) 2020-10-16

Similar Documents

Publication Publication Date Title
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
DOP2017000047A (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
ECSP18082207A (es) Neoantígenos y métodos de su uso
BR112018010084A2 (pt) ligantes de pd1 e/ou lag3
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
BR112018012352A2 (pt) anticorpos anti-lag3 e fragmentos de ligação ao antígeno
CU20170169A7 (es) Anticuerpos de factor xi
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201790961A1 (ru) Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения
BR112017020054A2 (pt) anticorpos para icos
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
PE20171764A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
BR112018009972A2 (pt) ligantes de ctla4
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
UY37030A (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
CR20160593A (es) Anticuerpos antagonistas del interferon alfa y omega
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
CO2021007882A2 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
AR118787A1 (es) Moléculas de unión a pd-l1 y uso de las mismas para el tratamiento de enfermedades